Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria
Authors: Alejandro Llanos-Cuentas
Marcus V.G. Lacerda
Tran T. Hien
Iván D. Vélez
Chayadol Namaik-Larp
Cindy S. Chu
Maria F. Villegas
Fernando Val
Wuelton M. Monteiro
Marcelo A.M. Brito
Mônica R.F. Costa
Raul Chuquiyauri
Martín Casapía
Chau H. Nguyen
Sandra Aruachan
Ratchadaporn Papwijitsil
François H. Nosten
Germana Bancone
Brian Angus
Stephan Duparc
Graham Craig
Victoria M. Rousell
Siôn W. Jones
Elizabeth Hardaker
Donna D. Clover
Lindsay Kendall
Khadeeja Mohamed
Gavin C.K.W. Koh
Viviana M. Wilches
John J. Breton
Justin A. Green
GlaxoSmithKline, USA
Universidad Peruana Cayetano Heredia
Universidad de Antioquia
University of Oxford
Fundacao Oswaldo Cruz
GlaxoSmithKline plc.
Mahidol University
Medicines for Malaria Venture
IMAT Onco-medica
Centro de Investigaciones Clínicas
Oxford University Clinical Research Unit
Keywords: Medicine
Issue Date: 17-Jan-2019
Citation: New England Journal of Medicine. Vol.380, No.3 (2019), 229-241
Abstract: Copyright © 2019 Massachusetts Medical Society. BACKGROUND Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed “radical cure.” METHODS We performed a phase 3, prospective, double-blind, double-dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2:1 ratio, to receive a single 300-mg dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision); all patients received a 3-day course of chloroquine and were followed for 180 days. The primary safety outcome was a protocol-defined decrease in the hemoglobin level (3.0 g per deciliter or ≥30% from baseline or to a level of 6.0 g per deciliter). Freedom from recurrence of P. vivax parasitemia at 6 months was the primary efficacy outcome in a planned patient-level meta-analysis of the current trial and another phase 3 trial of tafenoquine and primaquine (per-protocol populations), and an odds ratio for recurrence of 1.45 (tafenoquine vs. primaquine) was used as a noninferiority margin. RESULTS A protocol-defined decrease in the hemoglobin level occurred in 4 of 166 patients (2.4%; 95% confidence interval [CI], 0.9 to 6.0) in the tafenoquine group and in 1 of 85 patients (1.2%; 95% CI, 0.2 to 6.4) in the primaquine group, for a between-group difference of 1.2 percentage points (95% CI, −4.2 to 5.0). In the patient-level meta-analysis, the percentage of patients who were free from recurrence at 6 months was 67.0% (95% CI, 61.0 to 72.3) among the 426 patients in the tafenoquine group and 72.8% (95% CI, 65.6 to 78.8) among the 214 patients in the primaquine group. The efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for recurrence, 1.81; 95% CI, 0.82 to 3.96). CONCLUSIONS Among patients with normal G6PD enzyme activity, the decline in hemoglobin level with tafenoquine did not differ significantly from that with primaquine. Tafenoquine showed efficacy for the radical cure of P. vivax malaria, although tafenoquine was not shown to be noninferior to primaquine.
ISSN: 15334406
Appears in Collections:Scopus 2019

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.